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As NAD+ is a rate-limiting cosubstrate for the sirtuin
enzymes, its modulation is emerging as a valuable
tool to regulate sirtuin function and, consequently,
oxidative metabolism. In line with this premise,
decreased activity of PARP-1 or CD38—both NAD+
consumers—increases NAD+ bioavailability, result-
ing in SIRT1 activation and protection against meta-
bolic disease. Here we evaluated whether similar
effects could be achieved by increasing the supply
of nicotinamide riboside (NR), a recently described
natural NAD+ precursor with the ability to increase
NAD+ levels, Sir2-dependent gene silencing, and
replicative life span in yeast. We show that NR
supplementation in mammalian cells and mouse
tissues increases NAD+ levels and activates SIRT1
and SIRT3, culminating in enhanced oxidative
metabolism and protection against high-fat diet-
induced metabolic abnormalities. Consequently,
our results indicate that the natural vitamin NR could
be used as a nutritional supplement to ameliorate
metabolic and age-related disorders characterized
by defective mitochondrial function.
INTRODUCTION
The administration of NAD+ precursors, mostly in the form of
nicotinic acid (NA), has long been known to promote beneficial
effects on blood lipid and cholesterol profiles and even to induce
short-term improvement of type 2 diabetes (Karpe and Frayn,
2004). Unfortunately, NA treatment often leads to severe flush-
ing, resulting in poor patient compliance (Bogan and Brenner,
2008). These side effects are mediated by the binding of NA to838 Cell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc.the GPR109A receptor (Benyo et al., 2005). We hence became
interested in the possible therapeutic use of alternative NAD+
precursors that do not activate GPR109A.
NR was recently identified as a NAD+ precursor, with
conserved metabolism from yeast to mammals (Bieganowski
and Brenner, 2004). Importantly, NR is found in milk (Bieganow-
ski and Brenner, 2004), constituting a dietary source for NAD+
production. Once it enters the cell, NR is metabolized into nico-
tinamidemononucleotide (NMN) by a phosphorylation step cata-
lyzed by the nicotinamide riboside kinases (NRKs) (Bieganowski
and Brenner, 2004). In contrast to NR, NMN has not yet been
found in dietary constituents, and its presence in serum is
a matter of debate (Hara et al., 2011; Revollo et al., 2007). This
highlights how NR might be an important vehicular form of
a NAD+ precursor whose levels could be modulated through
nutrition.
The sirtuins are a family of enzymes that use NAD+ as
a cosubstrate to catalyze the deacetylation and/or mono-ADP-
ribosylation of target proteins. One of their major particularities
is that their Km for NAD
+ is relatively high, making NAD+ a rate-
limiting substrate for their reaction (Canto and Auwerx, 2012).
Initial work by yeast biologists indicated that the activity of Sir2
(the yeast SIRT1 homolog) as a NAD+-coupled enzyme could
provide a link between metabolism and gene silencing (Imai
et al., 2000a; Imai et al., 2000b). In this way, Sir2 was proposed
to mediate metabolic transcriptional adaptations linked to situa-
tions of nutrient scarcity, which are generally coupled to
increased NAD+ levels (for review, see Houtkooper et al.,
2010). During the last decade, an overwhelming body of
evidence indicates that the activity of mammalian sirtuins,
most notably SIRT1 and SIRT3, have the ability to enhance fat
oxidation and prevent metabolic disease (Hirschey et al., 2011;
Lagouge et al., 2006; Pfluger et al., 2008). Therefore, strategies
aimed to increase intracellular NAD+ levels have gained interest
in order to activate sirtuins and battle metabolic damage. Valida-
tion of this concept was achieved recently, by demonstrating
that pharmacological and genetic approaches aimed to reduce
0,3 
0,6 
0,9 
1,2 
0 200 400 600 800 1000 
NAD
+
 content 
 (mmol / kg of prot) 
C2C12 
Hepa1.6 
HEK293T 
Nicotinamide Riboside (µM) 
0 
0,5 
1 
1,5 
C2C12 Hepa1.6 HEK293T 
NAD
+
 content 
 (mmol / kg of prot) 
Veh          NR 
NMN        NA
* 
* 
* 
* 
* 
* 
* * * 
A
0 
0,25 
0,5 
0,75 
Liver Muscle 
* 
* * * 
* 
NAD
+
 content 
 (mmol / kg of prot) 
GPR109A-induced 
calcium mobilization  
(RLU – increase over basal) 
0 
1000 
2000 
3000 
4000 
10
-9 
10
-8 
10
-7 
10
-6 
10
-5 
10
-4 10
-3 
Concentration (M) 
NR 
NMN 
NA
E 
0 
1 
2 
3 
M
i
t
o
c
h
o
n
d
r
i
a
l
 
 
N
A
D
+
 
l
e
v
e
l
s
 
(
m
m
o
l
 
/
 
k
g
 
p
r
o
t
)
 
* 
Nampt
Tubulin
P
A
R
PARP-1 
0 
0,5 
1 
1,5 
N
a
m
p
t
 
m
R
N
A
 
l
e
v
e
l
s
 
(
r
e
l
a
t
i
v
e
 
t
o
 
V
e
h
)
 
Veh         NR Veh         NR 
B C D 
F G H 
0 
0,5 
1 
1,5 
2 
N
A
D
+
 
c
o
n
t
e
n
t
 
i
n
 
 
l
i
v
e
r
 
m
i
t
o
c
h
o
n
d
r
i
a
 
(
m
m
o
l
 
/
 
k
g
 
p
r
o
t
)
 
* 
Figure 1. Nicotinamide Riboside Supplementation Increases NAD+ Content and Sirtuin Activity in Cultured Mammalian Cells
(A) C2C12 myotubes, Hepa1.6, and HEK293T cells were treated with nicotinamide riboside (NR) for 24 hr, and acidic extracts were obtained to measure total
NAD+ intracellular content.
(B) GPR109A-expressing Chem-4 cells were loaded with 3 mM Fura-2 acetoxymethyl ester derivative (Fura-2/AM) for 30 min at 37C. Then cells were washed
three times with Hank’s balanced salt solution. Finally, calcium fluxes in response to increasing concentrations of nicotinic acid (NA; as positive control), NR, or
nicotinamide mononucleotide (NMN) were determined as indicated in the Experimental Procedures.
(C) C2C12 myotubes, Hepa1.6, and HEK293T cells were treated with either PBS (as vehicle) or 0.5 mM of NR, NMN, or NA for 24 hr. Then total NAD+ intracellular
content was determined as in (A).
(D) C57Bl/6J mice were fed with chow containing vehicle (water) or either NR, NMN,or NA at 400 mg/kg/day (n = 8 mice per group). After 1 week, NAD+ content
was determined in liver and quadriceps muscle.
(E) HEK293T cells were treated with NR (0.5 mM, black bars) or vehicle (white bars) for 4 hr. Then cells were harvested, and mitochondria were isolated for NAD+
measurement.
(F) C57Bl/6J mice were fed with chow containing vehicle (water) or NR at 400 mg/kg/day (n = 8 mice per group). After 1 week, mitochondria were isolated from
their livers to measure NAD+ content.
(G) HEK293T cells were treated with either PBS (as vehicle) or 0.5 mM of NR for 24 hr. Then mRNA and protein was extracted to measure Nampt levels by
RT-qPCR and western blot, respectively.
(H) HEK293T cells were treated with either PBS (as vehicle) or 0.5 mM of NR for 24 hr. Then protein homogenates were obtained to test global PARylation and
PARP-1 levels. Throughout the figure, all values are presented asmean ±SD. Asterisk indicates statistical significant difference versus respective vehicle group at
p < 0.05. Unless otherwise stated, the vehicle groups are represented by white bars, and NR groups are represented by black bars.
Cell Metabolism
NR Increases NAD+ and Prevents Metabolic Disordersthe activity of major NAD+-consuming activities in the cell, such
as PARP-1 (Bai et al., 2011b) and CD38 (Barbosa et al., 2007),
prompted an increase in NAD+ bioavailability and enhanced
SIRT1 activity, ultimately leading to effective protection against
metabolic disease. In this work we aimed to test whether similar
effects could be achieved through dietary supplementation with
a natural NAD+ precursor, such as NR.
RESULTS
NR Increases Intracellular and Mitochondrial NAD+
Content in Mammalian Cells and Tissues
NR treatment dose-dependently increased intracellular NAD+
levels in murine and human cell lines (Figure 1A), with maximalCeffects at concentrations between 0.5 and 1 mM. In C2C12 my-
otubes, the Km for NR uptakewas 172.3 ± 17.6 mM,with a Vmax of
204.2 ± 20.5 pmol/mg of protein/min. Unlike NA, both NR and
another well-described NAD+ precursor, NMN (Revollo et al.,
2007), did not activate GPR109A (Figure 1B), hence constituting
valuable candidates to increase NAD+ levels without activating
GPR109A. Strikingly, the ability of NR to increase intracellular
NAD+ in mammalian cells was, at least, similar to that of these
other precursors (Figure 1C). We next evaluated the efficacy of
NR, NMN, and NA to increase NAD+ in vivo by supplementing
mouse chow with NR, NMN, or NA at 400 mg/kg/day for
1 week. All compounds increased NAD+ levels in liver, but only
NR and NA significantly enhanced muscle NAD+ content. (Fig-
ure 1D). These results illustrate how NR administration is a validell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc. 839
Cell Metabolism
NR Increases NAD+ and Prevents Metabolic Disorderstool to boost NAD+ levels in mammalian cells and tissues without
activating GPR109A.
Given the existence of different cellular NAD+ pools and the
relevance of mitochondrial NAD+ content for mitochondrial and
cellular function (Yang et al., 2007a), we also analyzed whether
NR treatment would affect mitochondrial NAD+ levels. In
contrast to what has been observed with other strategies aimed
to increase NAD+ bioavailability, such as PARP inhibition (Bai
et al., 2011a), we found that mitochondrial NAD+ levels were
enhanced in cultured cells (Figure 1E) andmouse liver (Figure 1F)
after NR supplementation.
To further solidify our data, we also wondered whether the
enhanced NAD+ levels upon NR treatment could derive from
alterations in the NAD+ salvage pathway or PARP activity.
However, we could not see any change in Nampt mRNA or
protein content in response to NR treatment (Figure 1G). Simi-
larly, PARP activity and PARP-1 content were not affected by
NR (Figure 1H). Altogether, these results suggest that NR
increases NAD+ by direct NAD+ biosynthesis rather than by indi-
rectly affecting the major NAD+ salvage (Nampt) or consumption
(PARPs) pathways. Importantly, this increase in NAD+ was not
linked to changes in cellular glycolytic rates or ATP levels (data
not shown), which would be expected if NAD+/NADH ratios
had been altered to the point of compromising basic cellular
functions.
NR Treatment Enhances SIRT1 and SIRT3 Activity
The ability of NR to increase intracellular NAD+ levels both in vivo
and in vitro prompted us to test whether it could activate sirtuin
enzymes. Confirming this hypothesis, NR dose-dependently
decreased the acetylation of FOXO1 (Brunet et al., 2004) in
a SIRT1-dependent manner (Figure 2A). This deacetylation of
FOXO1 by SIRT1 upon NR treatment resulted in its transcrip-
tional activation, leading to higher expression of target genes,
such as Gadd45, Catalase, Sod1, and Sod2 (see Figure S1 on-
line) (Calnan and Brunet, 2008). The lack of changes in SIRT1
protein levels upon NR treatment (Figure 2A) suggests that NR
increases SIRT1 activity by enhancing NAD+ bioavailability.
The higher SIRT1 activity in NR-treated cells was supported by
mRNA expression analysis. Consistent with SIRT1 being a nega-
tive regulator of Ucp2 expression (Bordone et al., 2006), NR
decreased Ucp2mRNA levels (Figure 2B). Importantly, knocking
down Sirt1 prevented the action of NR on Ucp2 expression (Fig-
ure 2B). Similarly, the higher expression of a FOXO1 target gene,
Sod2, upon NR treatment was also prevented by the knockdown
of either Foxo1 or Sirt1 (Figure 2B). This suggested that NR leads
to a higher Sod2 expression through the activation of SIRT1,
which then deacetylates and activates FOXO1. Importantly, the
knockdown of Sirt1 did not compromise the ability of NR to
increase intracellular NAD+ content, indicating that NR uptake
and metabolism into NAD+ are not affected by SIRT1 deficiency
(Figure 2C).
In line with the increase in mitochondrial NAD+ levels (Figures
1E and 1F) and the potential consequent activation of mitochon-
drial sirtuins, NR also reduced the acetylation status of Ndufa9
immunoprecipitates and SOD2 (Figures 2D and 2E, respec-
tively), both targets for SIRT3 (Ahn et al., 2008; Qiu et al.,
2010). SOD2 deacetylation has been linked to a higher intrinsic
activity. In line with these observations, NR treatment enhanced840 Cell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc.SOD2 activity (Figure 2E). To ensure that NR-induced SOD2 de-
acetylation was consequent to SIRT3 activation, we usedmouse
embryonic fibroblasts (MEFs) established from SIRT3 KO mice.
The absence of SIRT3 was reflected by the higher basal acetyla-
tion of SOD2 (Figure 2F). Importantly, NR was unable to
decrease the acetylation status of SOD2 in SIRT3/ MEFs (Fig-
ure 2F), even though NAD+ levels increased to similar levels as in
SIRT3+/+MEFs (Figure 2G). These results clearly indicate that NR
triggers SIRT3 activity, probably by increasing mitochondrial
NAD+ levels, inducing the concomitant deacetylation of its mito-
chondrial targets. Strikingly, not all sirtuins were affected by NR,
as the acetylation of tubulin, a target of the cytoplasmic SIRT2
(North et al., 2003), was not altered (data not shown).
NR Supplementation Enhances Energy Expenditure
Given the promising role of sirtuins to protect against metabolic
disease, we next evaluated the effects of long-term NR adminis-
tration in vivo. We fed 10-week-old male C57Bl/6J mice with
either chow diet (CD) or high-fat diet (HFD), supplemented or
not with NR at 400 mg/kg/day. While NR had no effect on the
body weight (BW) on CD, HFD-induced BW gain was signifi-
cantly attenuated by NR (Figure 3A), due to reduced fat mass
(Figure 3B). This was visibly translated into a significant lower
weight of the epididymal depot in NR-fed mice (Figure S2A).
Importantly, this was not due to redistribution of lipids to other
tissues (Figure S2A), most notably to liver, which actually con-
tained 40% less triglycerides (Figure S2B).
The reduced BW gain of NR-fed mice upon HFD was not due
to reduced food intake, as NR-fed mice actually had a tendency
to eat more, especially on HFD conditions (Figure 3C). Similarly,
NR did not affect the activity pattern of mice (Figure 3D), indi-
cating that the lower BWonHFDwas not consequent to different
physical activity. Rather, the phenotype was due to enhanced
energy expenditure (EE). Mice on CD had a marked tendency
to display higher O2 consumption rates when fed with NR, and
this tendency became clearly significant under HFD conditions
(Figure 3E). Of note, NR-fed mice became more flexible in their
use of energy substrates, as reflected in the higher amplitude
of the changes in RER between feeding and fasting periods (Fig-
ure S2C) in CD conditions. Altogether, these results indicate that
NR lowers HFD-induced BW gain by enhancing EE.
From a metabolic perspective, NR- and vehicle-fed mice had
similar fasting blood glucose levels in either CD or HFD condi-
tions (Figure 3F). However, fasting insulin levels weremuch lower
in NR-supplementedmice (Figure 3G). This lower insulin/glucose
ratio is indicative of insulin sensitization after NR administration.
This speculation was further supported by glucose tolerance
tests. NR promoted a slight, albeit not significant, improvement
in glucose tolerance (Figure 3H) inmice fed a HFD, accompanied
by a robust reduction in insulin secretion (Figure 3I). Therefore,
NR-fedmice onHFD display a better glucose disposal with lower
insulin levels. In order to conclusively establish whether NR
fed mice were more insulin sensitive, we performed insulin toler-
ance tests and hyperinsulinemic-euglycemic clamps on CD and
CD-NR mice. We chose not to perform this analysis on the HFD
groups in order to avoid the possible influence of differential BW.
Glucose disposal upon insulin delivery was largely enhanced in
NR-fed mice (Figure 3J). In agreement, mice supplemented
with NR required an almost 2-fold higher glucose infusion rate
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Figure 2. Nicotinamide Riboside Supplementation Increases Sirtuin Activity in Cultured Mammalian Cells
(A) HEK293T cells were transfected with a pool of either scramble siRNAs or SIRT1 siRNAs. After 24 hr, cells were treated with vehicle (PBS) or NR at the
concentrations indicated, and, after an additional 24 hr, total protein extracts were obtained. FOXO1 acetylation was tested after FOXO1 immunoprecipitation (IP)
from 500 mg of protein, while tubulin and SIRT1 levels were evaluated in the supernatant of the IP.
(B) HEK293T cells were transfectedwith a pool of either scramble siRNAs, FOXO1 siRNAs, or SIRT1 siRNAs. After 24 hr, cells were treated with NR (0.5mM; black
bars) or vehicle (PBS; white bars) for an additional 24 hr. Then total mRNAwas extracted and themRNA expression levels of themarkers indicatedwere evaluated
by qRT-PCR.
(C) HEK293T cells were transfectedwith a pool of either scramble siRNAs, FOXO1 siRNAs, or SIRT1 siRNAs. After 24 hr, cells were treatedwith NR (0.5mM; black
bars) or vehicle (PBS; white bars) for an additional 24 hr. Then acidic extracts were obtained to measure intracellular NAD+ levels.
(D and E) HEK293T cells were treated with NR (0.5 mM) or vehicle (PBS) for 24 hr and total protein extracts were obtained to measure (D) Ndufa9 or (E) SOD2
acetylation after IP. The extracts were also used to measure SOD2 activity (E, bottom panel).
(F and G) SIRT3+/+ and SIRT3/mouse embryonic fibroblasts (MEFs) were treated with NR (0.5 mM) or vehicle (PBS) for 24 hr, and either (F) total extracts to test
SOD2 acetylation were obtained or (G) acidic extracts were used to measure intracellular NAD+ content. Throughout the figure, all values are presented as
mean ±SD. Asterisk indicates statistical significant difference versus respective vehicle group at p < 0.05. Unless otherwise stated, the vehicle groups are
represented by white bars, and NR groups are represented by black bars. This figure is complemented by Figure S1.
Cell Metabolism
NR Increases NAD+ and Prevents Metabolic Disordersto maintain euglycemia in hyperinsulinemic-euglycemic clamps
(Figure 3K). Together, these observations unequivocally demon-
strate that NR-fed mice are more insulin sensitive. Furthermore,
NR partially prevented the increase in total (Figure 3K) and LDL
cholesterol levels (Figure S2D) induced by HFD, even though
HDL-cholesterol levels were unaffected (Figure S2E). The
amelioration of cholesterol profiles is fully in line with previous
observations from the use of other NAD+ precursors, such as
NA (Houtkooper et al., 2010).
NR Enhances the Oxidative Performance of Skeletal
Muscle and Brown Adipose Tissue
NR-fed mice had a clear tendency to display a better endurance
performance than vehicle-fed mice (Figure S3A). This tendencyCwas significantly accentuated upon HFD (Figure 4A), suggesting
an enhanced muscle oxidative performance. Similarly, NR-fed
mice, both on CD and HFD, showed enhanced thermogenic
capacity, as manifested in the ability to maintain body tempera-
ture during cold exposure (Figure S3B and Figure 4B). The latter
observation hints toward an improvement in brown adipose
tissue (BAT) oxidative performance. To gain further insight into
the ability of BAT and muscle to enhance their oxidative perfor-
mance, we performed some histological analysis. Gastrocne-
mius muscles from NR mice displayed a more intense SDH
staining than gastrocnemius muscles from their vehicle-fed
littermates, indicating a higher oxidative profile (data not shown).
Electron microscopy revealed that mitochondria in BAT of
NR-fed mice, despite not being significantly larger, had moreell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc. 841
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Figure 3. NR Supplementation Prevents Diet-Induced Obesity by Enhancing Energy Expenditure and Reduces Cholesterol Levels
Ten-week-old C57Bl/6J mice were fed with either chow diet (CD) or high-fat diet (HFD) mixed with either water (as vehicle) or NR (400 mg/kg/day) (n = 10 mice
per group).
(A) Body weight evolution was monitored for 12 weeks.
(B) Body composition was evaluated after 8 weeks of diet through Echo-MRI.
(C–E) Food intake, activity, and VO2 were evaluated using indirect calorimetry.
(F and G) Blood glucose and insulin levels were measured in animals fed with their respective diets for 16 weeks after a 6 hr fast.
(H and I) After 10 weeks on their respective diets (CD, squares; HFD, circles), an intraperitoneal glucose tolerance test was performed in mice that were fasted
overnight. At the indicated times, blood samples were obtained to evaluate either (H) glucose or (I) insulin levels. Areas under the curve are shown at the top right
of the respective panels.
(J) Insulin tolerance tests were performed on either CD or CD-NR mice (4 weeks of treatment). At the indicated times, blood samples were obtained to evaluate
blood glucose levels. The area above the curve is shown at the top right of the panel.
(K) Hyperinsulinemic-euglycemic clamps were performed on either CD or CD-NR mice (4 weeks of treatment). Glucose infusion rates (GIR) were calculated after
the test.
(L) Serum levels of total cholesterol weremeasured in animals fed with their respective diets for 16weeks, after a 6 hr fast. Throughout the figure, white represents
the vehicle group, and black represents the NR-supplemented mice. All values are presented as mean ±SD. Asterisk indicates statistical significant difference
versus respective vehicle-treated group. This figure is complemented by Figure S2.
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NR Increases NAD+ and Prevents Metabolic Disordersabundant cristae (Figure 4C), which has been linked to
increased respiratory capacity (Mannella, 2006). Altogether,
the above results suggest that NR-supplemented mice display
a higher oxidative capacity due to enhanced mitochondrial
function.
Chronic NR Feeding Increases NAD+ In Vivo in a Tissue-
Specific Manner
We next wondered how chronic NR feeding would affect NAD+
metabolism in mice. Chronic NR supplementation increased
NAD+ levels in both CD (Figure S4A) and HFD (Figure 5A) condi-
tions in some tissues, including liver and muscle, but not in
others, such as brain or white adipose tissue (WAT). Interest-842 Cell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc.ingly, NAD+ was also higher in the BAT of NR-fed mice, but
only on HFD (Figure 5B and Figure S4A). These differences could
be due to the differential expression of NRKs in tissues. NRKs
initiate NR metabolism into NAD+ (Houtkooper et al., 2010).
There are two mammalian NRKs: NRK1 and NRK2 (Bieganowski
and Brenner, 2004). While we foundNrk1 expressed ubiquitously
(Figure S4B), Nrk2 was mainly present in cardiac and skeletal
muscle tissues, as previously described (Li et al., 1999), but
also detectable in BAT and liver (Figure S4C), in line with the
better ability of these tissues to respond to NR.
We also tested whether the increase in NAD+ would be
concomitant to changes in other NAD+ metabolites. Strikingly,
NADH and nicotinamide (NAM) levels were largely diminished
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Figure 4. NR Enhances Skeletal Muscle and BAT Oxidative Function
Ten-week-old C57Bl/6J mice were fed a high-fat diet (HFD) mixed with either
water (as vehicle; white bars and circles) or NR (400mg/kg/day; black bars and
circles) (n = 10 mice per group).
(A) An endurance exercise test was performed using a treadmill in mice fed
with either HFD or HFD-NR for 12 weeks.
(B) A cold test was performed in mice fed with either HFD or HFD-NR for
9 weeks. The area over the curve (AOC) is shown on the top right of the graph.
(C) Electron microscopy of the BATwas used to analyze mitochondrial content
and morphology. The size and cristae content of mitochondria were quantified
as specified in the Experimental Procedures. Throughout the figure, all values
are shown as mean ±SD. Asterisk indicates statistical significant difference
versus vehicle-supplemented group at p < 0.05. This figure is complemented
by Figure S3.
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NR Increases NAD+ and Prevents Metabolic Disordersin muscles from NR-fed mice (Figure 5B), indicating that NR
specifically increases NAD+, but not necessarily other byprod-
ucts of NAD+ metabolism. We analyzed in vivo whether the
activity of major NAD+-degrading enzymes or the levels of
Nampt could also contribute to the increase in NAD+ after
chronic NR supplementation. As previously observed in
HEK293T cells (Figures 1G and 1H), PARP-1 levels and global
PARylation were similar in muscle (Figure 5C) and livers (Fig-
ure S4D) from NR- and vehicle-fed mice, indicating that the
enhanced NAD+ content cannot be explained by differential
NAD+ consumption through PARP activity. Nampt mRNA (Fig-
ure 5D) and protein (Figure 5C, Figure S4E, and data not shown)
levels were also similar in NR- and vehicle-fed mice, suggestingCthat NAD+ salvage pathways do not explain the differences in
NAD+ levels. We furthermore could not detect differences in
mRNA expression of the different NMN adenylyltransferase
(NMNAT) enzymes (Figure 5D). Altogether, these results rein-
force the notion that the higher NAD+ levels observed in tissues
from NR-fed mice are consequent to an increase in direct NAD+
synthesis from NR.
NR Enhances Sirtuin Activity In Vivo
Higher NAD+ levels were also accompanied by higher sirtuin
activity in vivo. A prominent deacetylation of SIRT1 and
SIRT3 targets (FOXO1, Brunet et al., 2004; and SOD2 Qiu
et al., 2010, respectively) was observed in the skeletal muscle,
liver, and BAT, where NAD+ content was induced by NR, but
not in brain and WAT, where NAD+ levels were unaffected by
NR supplementation (Figure 6A and Figure S5A). We also eval-
uated PGC-1a acetylation as a second readout of SIRT1
activity (Rodgers et al., 2005). We were unable to detect
PGC-1a in total lysates from WAT or brain (Figure S5B), but
in muscle, liver, and BAT, PGC-1a was deacetylated upon
NR treatment (Figure S5C). These observations highlight how
NR can only induce sirtuin activity in tissues where NAD+ accu-
mulates. Like in cultured cells, we could not detect changes in
the acetylation status of the SIRT2 target tubulin (data not
shown), suggesting either that increasing NAD+ might not affect
the activity of all sirtuins equally, that the increase is only
compartment specific, or that additional regulatory elements,
like class I and II HDACs, also contribute to tubulin acetylation
status.
In line with the changes in acetylation levels of PGC-1a, a
key transcriptional regulator of mitochondrial biogenesis, we
could observe either an elevated expression or a strong
tendency toward an increase (p < 0.1) of nuclear genes encoding
transcriptional regulators of oxidative metabolism (Sirt1,
Ppargc1a, mitochondrial transcription factor A [Tfam]) and mito-
chondrial proteins (Mitofusin 2 [Mfn2], cytochrome c [Cycs],
medium-chain acyl-coA dehydrogenase [Acadm], carnitine
palmitoyltransferase-1b [Cpt1b], citrate synthase [Cs], or ATP
synthase lipid binding protein [Atp5g1]) in quadriceps muscles
from NR-fed mice (Figure 6B). Conversely, in brain, where
NAD+ and sirtuin activity levels were not affected by NR feeding,
the expression of these genes was not altered (Figure 6B).
Consistently also with enhanced mitochondrial biogenesis,
mitochondrial DNA content was increased in muscle, but not in
brain from NR-fed mice (Figure 6C). Finally, mitochondrial
protein content also confirmed that mitochondrial function was
only enhanced in tissues in which NAD+ content was increased
(Figure 6D and Figure S5D). This way, while muscle, liver, and
BAT showed a prominent increase in mitochondrial proteins
(complex V—ATP synthase subunit a and porin), such change
was not observed in brain or WAT. Altogether, these results
suggest that NR feeding increases mitochondrial biogenesis in
a tissue-specific manner, consistent with the tissue-specific
nature of the increases in NAD+ and sirtuin activity observed in
NR-fed mice. The higher number of mitochondria, together
with the different morphological mitochondrial profiles found in
NR-fed mice (Figure 4C), would contribute to explain the higher
oxidative profile, EE, and protection against metabolic damage
observed upon NR feeding.ell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc. 843
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Figure 5. Chronic NR Supplementation Increases
Plasma and Intracellular NAD+ Content in
a Tissue-Specific Manner
Tissues fromC57Bl/6Jmice were collected after 16 weeks
of HFD supplemented with either water (as vehicle; white
bars) or NR (400 mg/kg/day; black bars).
(A) NAD+ levels were measured in acidic extracts obtained
from different tissues.
(B) NADH and NAM levels were measured in gastrocne-
mius muscle.
(C) Quadriceps muscle protein homogenates were ob-
tained to test global PARylation, PARP-1, and Nampt
protein levels.
(D) Total mRNA was isolated from quadriceps muscles,
and the mRNA levels of the markers indicated were
measured by RT-qPCR. Throughout the figure, all values
are expressed as mean ±SD. Asterisk indicates statistical
significant difference versus respective vehicle-treated
group.
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While increased NAD+ levels in response to NR supplementation
were already reported in yeast (Belenky et al., 2007; Bieganow-
ski and Brenner, 2004) and cultured human cells (Yang et al.,
2007b), we extend these observations to a wide range of
mammalian cell lines and demonstrate that NR supplementation
also enhances NAD+ bioavailability in mammalian tissues. Also,
our work provides evidence that the increase in NAD+ after NR
administration stimulates the activity of mammalian sirtuins.
This further supports the role of sirtuins as a family of proteins
whose basal activity can be largely modulated by NAD+ avail-
ability (Houtkooper et al., 2010).
The fact that the activity of both SIRT1 and SIRT3 is positively
regulated by NR both in vitro and in vivo favors the hypothesis
that the increase in NAD+ promoted by NR affects, at least, the
mitochondrial and the nuclear compartments. This is a key differ-
ence compared to other strategies that boost intracellular NAD+
levels. For example, Parp-1 knockout mice show a 2-fold
increase in intracellular NAD+, yet SIRT3 activity is not affected
(Bai et al., 2011b). Given that PARP-1 is a nuclear enzyme, it is
tempting to hypothesize that, in the Parp-1 knockout mice, the
increase in NAD+ is mainly confined to the nucleus, while the
NR-induced increase inNAD+ levels, despite beingmore discrete
in amplitude, reaches different subcellular compartments.
The inability of NR to activate GPR109A illustrates how NR
provides an alternative way to increase NAD+ and ameliorate
metabolic homeostasis in the absence of the undesirable effects
seen with NA. Since NR does not activate GPR109A, we specu-
late that NR reduces cholesterol levels through the activation of
SIRT1 in liver, which influences the activity of a number of tran-
scription factors and cofactors linked to cholesterol homeostasis
(Kemper et al., 2009; Li et al., 2007; Shin et al., 2003; Walker
et al., 2010). Interestingly, the mechanism of action of NA on
VLDL/LDL and hepatic metabolism is not clear, as GPR109A is
not expressed in the liver (Tunaru et al., 2003). Our data raise
the possibility that NA, like NR, achieves such effects by844 Cell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc.elevating NAD+ levels, activating SIRT1 and its downstream
targets. However, future experiments will be required to verify
this hypothesis. The activation of SIRT1 and SIRT3, impacting
on targets such as PGC-1a, FOXOs, and SOD2, also provides
a likely explanation for the mitochondrial fitness and metabolic
flexibility of NR-supplemented mice. In this sense, it is remark-
able that while SIRT1 transgenic mice have some shared pheno-
types with NR-treatment mice, such as protection against
metabolic damage, there are also a number of discrepancies.
For example, SIRT1 transgenics show similar BW gain upon
HFD to wild-type littermates (Pfluger et al., 2008). The differ-
ences between NR-supplemented mice and SIRT1 trangenics
can be explained by numerous reasons. First, NR affects
different sirtuin activities; second, sirtuin expression does not
necessarily correspond with sirtuin activity; third, NR actions
are tissue specific. Importantly, we should also consider that
NR might trigger other actions unrelated to sirtuin activity that
might also contribute to the beneficial effects of NR (Figure 7).
In conclusion, our work shows that NR is a powerful supple-
ment to boostNAD+ levels, activate sirtuin signaling, and improve
mitochondrial function, suggesting that this vitamin could be
used to prevent and treat the mitochondrial decline that is a hall-
mark of many diseases associated with aging. Very recent work,
showing that intraperitoneal administration of NMN could
improve the metabolic damage induced by high-fat feeding
(Yoshino et al., 2011), further supports this concept. To date,
however, only NR has been identified as a naturally occurring
component of the human diet (Bieganowski and Brenner, 2004).
Furthermore, NR protects against metabolic dysfunction at lower
concentrations than those reported for NMN, andwe proved that
it is effective after oral administration when mixed with food, in
contrast to NMN, which is injected intraperitoneally (Yoshino
et al., 2011). So, how might NR and NMN biology intertwine and
impact on NAD+ synthesis in mammalian physiology? Recent
observations suggest that, at least for some cell types, NMN
needs to be converted into NR through dephosphorylation
performed by extracellular 50-nucleotidases in order to penetrate
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Figure 6. NR Stimulates Sirtuin Activity
In Vivo and Enhances Mitochondrial Gene
Expression
Tissues from C57Bl/6J mice were collected after
16 weeks of HFD supplemented with either water
(as vehicle; white bars) or NR (400 mg/kg/day;
black bars).
(A) Total protein extracts were obtained from
quadriceps muscle and brain as indicated to
evaluate the acetylation levels of FOXO1 and
SOD2 through immunoprecipitation assays, using
1 and 0.5 mg of protein, respectively.
(B) Total mRNA from quadriceps muscle and brain
was extracted to measure the abundance of the
markers indicated by RT-qPCR.
(C) Mitochondrial DNA content was measured in
DNA extracted from quadriceps muscle and brain.
The results are expressed as mitochondrial copy
number relative to genomic DNA.
(D) The abundance of mitochondrial marker
proteins in 20 mg of protein from total quadriceps
muscle and brain lysates. Throughout the figure,
all values are shown as mean ±SD. Asterisk indi-
cates statistical significant difference versus
vehicle-supplemented group at p < 0.05. This
figure is complemented by Figure S4.
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NR Increases NAD+ and Prevents Metabolic Disordersinto the cell (Nikiforov et al., 2011). Given that the presence of
NMN in plasma is debated (Hara et al., 2011), the most likely
scenario is that NR, rather than NMN, is the entity directly taken
up by the cell, to then become metabolized in the cytosolic
compartment to NMN. The lack of NRK1 and NRK2 in the mito-
chondrial compartment (Nikiforovet al., 2011) supports thenotion
that NMNmight act as the precursor entering themitochondria or
other compartments for further metabolism into NAD+ by the
various NMNAT enzymes (see Figure 7 for a scheme).Figure
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Cell Metabolism 15, 838–Our data, combined with the evidence
that other NAD+ precursors can improve
age-related insulin resistance (Yoshino
et al., 2011) and that NR increases yeast
replicative life span (Belenky et al.,
2007), therefore warrant future investiga-tions to see if boosting NAD+ levels by NR supplementation
might also improve the health and life span of humans.
EXPERIMENTAL PROCEDURES
Materials
All chemicals and reagents were purchased from Sigma-Aldrich unless stated
otherwise. NR was custom synthesized as previously described (Yang et al.,
2007b) and was kindly provided by Amazentis and Merck Research
Laboratories.7. Schematic Representation of the
nt Actions of NR in Metabolic Homeostasis
heme summarizes the hypothesis by which NR
entation would increase NAD+ content in key
lic tissues, leading to SIRT1 and SIRT3 activation
deacetylation and modulation of the activity of key
lic regulators. This model does not rule out the
ation of additional mechanisms of action for NR to
its beneficial effects. Abbreviations can be found
ext, and enzymes are indicated in italics.
847, June 6, 2012 ª2012 Elsevier Inc. 845
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Eight-week-old male C57Bl/6J mice were purchased from Charles River, and
powder chow (D12450B) and high-fat (D12492) dietswere fromResearchDiets
Inc. (NewBrunswick, NJ, USA). CD pellets weremade by adding 80ml of water
per kg of powder CD. HFDpellets weremade by adding 40ml of water per kg of
powder HFD. For NR-, NMN-, and NA-supplemented diets, the appropriate
amount of these compoundswas added to thewater used to create the pellets,
taking into account the differences in the daily intake of each diet. Mice were
housed separately, had ad libitum access to water and food, and were kept
under a 12 hr dark-light cycle. Mice were fed with homemade pellets from
10 weeks of age. To make the pellets, the powder food was mixed with water
(vehicle) or with NR. All animal experiments were carried according to national
Swiss and EU ethical guidelines and approved by the local animal experimen-
tation committee of the Canton de Vaud under license #2279.
Animal Phenotyping
Mice were weighed and food consumption was measured each week on the
same day. Most clinical tests were carried out according to standard opera-
tional procedures (SOPs) established and validated within the Eumorphia
program (Champy et al., 2008). Body composition was determined by Echo-
MRI (Echo Medical Systems, Houston, TX, USA), and oxygen consumption
(VO2), respiratory exchange ratios (RER), food intake, and activity levels
were monitored by indirect calorimetry using the comprehensive laboratory
animal monitoring system (Columbus Instruments, Columbus, OH, USA).
Treadmill, cold tests, and hyperinsulinemic-euglycemic clamps were per-
formed as described (Lagouge et al., 2006). Glucose and insulin tolerance
was analyzed bymeasuring blood glucose and insulin following intraperitoneal
injection of 2 g/kg glucose or 0.25 U insulin/kg, respectively, after an overnight
fast. Plasma insulin was determined in heparinized plasma samples using
specific ELISA kits (Mercodia). All animals were sacrificed at 13:00, after
a 6 hr fast, using CO2 inhalation. Blood samples were collected in heparinized
tubes, and plasma was isolated after centrifugation. All plasma parameters
were measured using a Cobas c111 (Roche Diagnostics). Tissues were
collected upon sacrifice and flash frozen in liquid nitrogen.
Histology and Microscopy
Succinate dehydrogenase staining and transmission electron microscopy
(TEM) were performed as described (Bai et al., 2011b). Mitochondrial size and
cristae content were analyzed as previously described (St-Pierre et al., 2003).
Cell Culture and Transfection
Murine C2C12 myoblasts were grown and differentiated into myotubes as
described (Canto et al., 2009). Murine Hepa1.6 and human HEK293T cells
were cultured in DMEM (4.5 g/l glucose, 10% FCS). Human FOXO1 and
SIRT1 siRNAs were obtained from Dharmacon (Thermo Scientific) and used
following the instructions from the manufacturer. SIRT3 MEFs were estab-
lished according to standard techniques (Picard et al., 2002) from conditional
SIRT3/ mice. Deletion of the SIRT3 gene was induced via infection with
adenovirus encoding for the Cre recombinase.
Gene Expression and Mitochondrial DNA Abundance
RNA was extracted and quantified by qRT-PCR as described (Lagouge et al.,
2006). The qPCR primers used have been previously described. Mitochondrial
DNA abundance (mtDNA) was quantified as described (Lagouge et al., 2006)
after isolating total DNA using a standard phenol extraction.
Immunoprecipitation, SDS-PAGE, Western Blotting
Cells were lysed in lysis buffer (50 mM Tris, 150 mM KCl, EDTA 1 mM, NP40
1%, nicotinamide 5 mM, Na-butyrate 1 mM, protease inhibitors [pH 7.4]).
Immunoprecipitation from cultured cells or tissue samples was performed
exactly as described (Canto et al., 2009). For western blotting, proteins were
separated by SDS-PAGE and transferred onto nitrocellulose membranes.
Anti-acetyl-lysine antibodies were from Cell Signaling; FOXO1 and SOD2 anti-
bodies were from Santa Cruz Biotechnology; SIRT1 and PGC-1a antibodies
were from Millipore; tubulin and acetyl-tubulin antibodies were from Sigma
Inc. Antibodies for mitochondrial markers were purchased fromMitosciences.
Antibody detection reactions were developed by enhanced chemilumines-
cence (Amersham, Little Chalfont, UK).846 Cell Metabolism 15, 838–847, June 6, 2012 ª2012 Elsevier Inc.NAD+, NADH, and NAM Determination
NAD+ levels were determined using a commercial kit (Enzychrom, BioAssays
Systems, CA), and tissue samples were also measured by HPLC (Ramsey
et al., 2009). Other NAD metabolites were determined as previously described
(Yang and Sauve, 2006).
GPR109A—Calcium Mobilization Assay
Ready-to-Assay GRP109A nicotinic acid receptor cells were used to measure
calcium mobilization as specified by the manufacturer (Millipore). Calcium flux
was determined using excitation at 340 and 380 nm in a fluorescence spectro-
photometer (VictorX4, Perkin Elmer) in a 180 s time course, adding the ligand at
60 s. Internal validation was made using 0.1% Triton X-100 for total fluoro-
phore release and 10 mM EGTA to chelate free calcium. Similarly, GPR109A
specificity was internally validated using control cells devoid of GRP109A
overexpression.
Liver Triglyceride Measurement
Liver triglycerides weremeasured from 20mg of liver tissue using a variation of
the Folch method, as described (Bai et al., 2011a).
Statistics
For the statistical analysis of the animal studies, all data were verified for
normal distribution. To assess significance, we performed Student’s t test
for independent samples. Values are expressed as mean ±SD unless other-
wise specified.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.cmet.2012.04.022.
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